High burden of clinically significant adverse events associated with contemporary therapy for pediatric T‐cell acute lymphoblastic leukemia/lymphoma

Author:

Summers Ryan J.12ORCID,Monroig Vanessa M.2,DeGroote Nicholas P.1,West Zachary E.2,Katafias Elizabeth1,Miller Tamara P.12ORCID

Affiliation:

1. Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta Atlanta Georgia USA

2. Department of Pediatrics Emory University School of Medicine Atlanta Georgia USA

Abstract

AbstractBackgroundDespite improvements in survival for children with T‐cell acute lymphoblastic leukemia and lymphoma (T‐ALL/LLy), morbidity remains high. However, data are lacking regarding comprehensive descriptions of clinically relevant adverse events (AEs) experienced during early intensive chemotherapy.ProcedureThis single‐institution retrospective study evaluated children aged 1–21 years with T‐ALL/T‐LLy diagnosed from 2010 to 2020. Physician chart abstraction identified and graded 20 clinically relevant AEs. AE rates were analyzed by T‐ALL or LLy, minimal residual disease status, induction steroid, and use of antimicrobial prophylaxis. Statistical comparisons used the Kruskal–Wallis test (continuous variables) and Chi‐square or Fisher's exact test (categorical variables).ResultsThe cohort included 120 patients (T‐ALL: 88; T‐LLy: 32). Most patients experienced AEs during induction (85 out of 120; 70.8%) and consolidation (89 out of 111; 80.2%). Nonsepsis infection was common in induction (26 out of 120; 21.7%) and consolidation (35 out of 111; 31.5%). Patients treated with dexamethasone during induction had significantly higher rates of nonsepsis infection and/or sepsis during consolidation than those who received prednisone (p < .01).ConclusionsClinically significant AEs are extremely common during induction and consolidation therapy for patients with T‐ALL/LLy. Infectious AEs are particularly prevalent. These results can inform conversations with patients and families and aid in the development of toxicity‐related aims in the next generation of, prospective clinical trials in T‐ALL/LLy.

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3